Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety

Back

ESC Professional Premium Access

Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety

Session: Rhythm control in atrial fibrillation: prognostic and therapeutic implications

Topic: Rhythm Control, Antiarrhythmic Drugs

Speaker: Doctor J. Mason (Salt Lake City, US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Jay Mason

University of Utah, Salt Lake City (United States of America)

0 follower

8 more presentations in this session

Cluster-specific predictors of early rhythm control in contemporary European cohort of patients with atrial fibrillation: The EHRA-PATHS Project

Speaker: Doctor M. Mihajlovic (Belgrade, RS)

Impact of rhythm control strategy on outcomes in patients with first diagnosed atrial fibrillation in an 11-year real-world registry

Speaker: Doctor C. Salbach (Heidelberg, DE)

Atrial function after cardioversion in patients with persistent atrial fibrillation

Speaker: Doctor K. Noda (Sendai, JP)

Sinus rhythm maintenance and the changes of echocardiographic parameters in patients with late persistent atrial fibrillation at 6 months after direct current cardioversion

Speaker: Doctor Y. Skybchyk (Kiev, UA)

H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.

Speaker: Mr M. Trincado Ave (Santiago de Compostela, ES)

Access the full session

Rhythm control in atrial fibrillation: prognostic and therapeutic implications

Speakers: Doctor J. Mason, Doctor M. Mihajlovic, Doctor C. Salbach, Doctor K. Noda, Doctor Y. Skybchyk...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources